NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-DK-20-046 from the NIH Guide for Grants and Contracts
Notice NOT-TW-20-007 from the NIH Guide for Grants and Contracts
Notice NOT-DK-20-045 from the NIH Guide for Grants and Contracts
Notice NOT-AG-20-048 from the NIH Guide for Grants and Contracts
Notice NOT-HL-20-813 from the NIH Guide for Grants and Contracts
Notice NOT-NS-20-102 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-20-041 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is for a Coordinating Center for the NCI Pediatric in Vivo Testing Program (henceforth termed the Ped-In Vivo-TP). The main goal for the Ped-InVivo-TP is to use genomically-characterized pediatric cancer models to develop a rigorous preclinical testing system to generate reliable data that can be used to inform new agent prioritization decisions for childhood cancers. The Ped-In Vivo-TP has two parts: a) research teams for in vivo testing to determine the activity of pediatric anticancer drug candidates, supported under RFA-CA-20-037); and b) a Coordinating Center (RFA-CA-20-041, this FOA). The Ped-InVivo-TP is envisioned as a way for NCI to support the Foundation for the National Institutes of Health (FNIH)-organized Public-Private Partnership (PPP) for pediatric preclinical testing. The PPP is being developed to accelerate the pace and to broaden the scope of pediatric preclinical testing of agents being developed for adult cancer indications. Pharmaceutical companies and representatives of regulatory agencies will also participate in the PPP. The Program Director(s)/Principal Investigator(s) [PD(s)/PI(s)] of the Ped-InVivo-TP Research Teams and Coordinating Center will be expected to serve on the Scientific Advisory Committee (SAC) of the FNIH PPP and will contribute to the SAC with regards to the research opportunities in their areas of expertise. This FOA invites applications for the Ped-InVivo-TP Coordinating Center. The Ped-InVivo-TP Coordinating Center will be responsible for integrating the activities of the individual Ped-InVivo-TP Research Teams to create a functional collaboration for pediatric preclinical testing. Specifically, the Ped-InVivo-TP Coordinating Center will be responsible for the following: 1) Administrative and logistical coordination; 2) Data management, statistical, and bioinformatics support; and 3) Scientific coordination and s
Funding Opportunity RFA-CA-20-034 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is for Research Teams to form the NCI Pediatric in Vivo Testing Program (henceforth termed the Ped-InVivo-TP). The Research Teams of the Ped-InVivo-TP will determine the activity of pediatric anticancer drug candidates using preclinical models relevant to the cancer(s) on which their team focuses (supported under this FOA) and will work in concert with the Ped-InVivo-TP Coordinating Center (supported under RFA-CA-20-041). The Research Teams will use genomically characterized pediatric cancer models to develop a rigorous preclinical testing program that will generate reliable data that can be used to inform new agent prioritization decisions for childhood cancer clinical testing. The Ped-InVivo-TP is envisioned as a way for NCI to support the Foundation for the National Institutes of Health (FNIH)-organized Public-Private Partnership (PPP) for pediatric preclinical testing. The PPP is being developed to accelerate the pace and to broaden the scope of pediatric preclinical testing of agents being developed for adult cancer indications. Pharmaceutical companies and representatives of regulatory agencies will also participate in the PPP. The Program Director(s)/Principal Investigator(s) [PD(s)/PI(s)] of the Ped-InVivo-TP Research Teams and Coordinating Center will be expected to serve on the Scientific Advisory Committee (SAC) of the FNIH PPP and will contribute to the SAC with regards to the research opportunities in their areas of expertise. This FOA invites applications from Research Teams that have developed panels of genomically characterized pediatric cancer models and that have the capacity for using their panels to test up to 8-10 agents per year. The Ped-InVivo-TP Awardees will work closely with the Ped-In Vivo-TP Coordinating Center in the testing of agents and in the analysis and reporting of testing results.
Notice NOT-HG-20-056 from the NIH Guide for Grants and Contracts
Notice NOT-DK-20-044 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NS-21-003 from the NIH Guide for Grants and Contracts. The goal of the Frontotemporal Dementia (FTD) Centers Without Walls (CWOW) is to improve our understanding of the mechanisms underlying neurodegeneration in FTD through multi-disciplinary, team-based science to address a specific challenge or challenges in the field that could not be achieved through individual research projects.
Notice NOT-HL-20-809 from the NIH Guide for Grants and Contracts
Notice NOT-EB-20-014 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-20-048 from the NIH Guide for Grants and Contracts. The purpose of the NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to encourage and retain outstanding graduate students recognized by their institutions for their high potential and strong interest in pursuing careers as independent cancer researchers. The award will facilitate the transition of talented graduate students into successful cancer research postdoctoral appointments, and provide opportunities for career development activities relevant to their long-term career goals of becoming independent cancer researchers. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.
Funding Opportunity PAR-20-292 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk, but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).
Funding Opportunity PAR-20-258 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide early-stage investigators with support and protected time (up to five years) for intensive, research-focused career development program activities under the guidance of an experienced mentorship team with expertise in both the preclinical application of nonhuman primate (NHP) models and in translation of the results from such studies to clinical application. The focus of this program is to increase the number of highly skilled scientists using NHP models to address complex translational biomedical research designed to foster translation of outcomes into the clinic. The expectation is that through this sustained period of research career development and training, awardees will launch independent research careers and become competitive for new research project grant (e.g., R01) funding. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor.
Funding Opportunity RFA-DK-20-022 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support multidisciplinary research teams with complementary expertise in HIV and pathobiology, pathophysiology, and/or metabolism in organs, tissues, and/or biological systems of specific interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). These teams will comprehensively interrogate fundamental mechanisms underlying HIV-associated comorbidities, coinfections, and complications relevant to the mission of the NIDDK and advance progress toward alleviating them.
Funding Opportunity RFA-ES-20-013 from the NIH Guide for Grants and Contracts. The purpose of the RESTORE program is to advance understanding of the role of inflammation resolution pathways at the cellular and molecular level and how exposure to environmental pollutants interferes with these pathways resulting in exposure-induced chronic systemic inflammation and ultimately chronic disease conditions. The initial phase of this program is focused on understanding how chronic exposure to air pollution interferes with resolution of inflammation in pulmonary, cardiovascular, and metabolic systems and diseases.
Notice NOT-CA-20-095 from the NIH Guide for Grants and Contracts
Notice NOT-EB-20-016 from the NIH Guide for Grants and Contracts